Stalevo

Utilized to manage neurological dysfunction to support motor control.

Strengths: 25/100/200mg

Medicine details

Therapeutic class

Dopaminergic Agent

Pharmacological class

Dopamine Precursor/COMT Inhibitor

Minor side effects

dyskinesia; nausea; dizziness; chromaturia

Moderate side effects

hallucinations; confusion; insomnia

Dosage forms

Film-coated tablet

Administration route

Oral use

Patient summary

Utilized to manage neurological dysfunction to support motor control.

Prescription status

POM

Manufacturer

Orion Pharma

Onset Time

0.5–2 hours

Duration

3–6 hours

Storage instructions

Keep container tightly closed and protect from light.

Drug interactions

Iron supplements; Antipsychotics

Age restrictions

Not for children.

Pregnancy and breastfeeding

Pregnancy: not recommended. Breastfeeding: not recommended.

Contraindications

hypersensitivity to components; narrow-angle glaucoma; pheochromocytoma; history of neuroleptic malignant syndrome; concurrent use of monoamine oxidase inhibitors

Precautions and warnings

may cause sudden sleep onset; may impair ability to drive; monitor for impulsive behaviour

Serious side effects

neuroleptic malignant syndrome — requires immediate medical attention; rhabdomyolysis — requires immediate medical attention

Mechanism of action

Combines a dopamine precursor to restore levels, a peripheral decarboxylase inhibitor to prevent systemic breakdown, and a COMT inhibitor to extend the duration of the dopamine effect in the brain.

Stalevo

Utilized to manage neurological dysfunction to support motor control.

Editorial Notes

  • Active ingredient(s): Carbidopa, Levodopa, Entacapone
  • Listed indication(s): Parkinson’s Disease

Available option

  • 90 tablets - 25/100/200 mg1124-25-100-200-mg-15628